171 results about "Hepatic inflammation" patented technology

The invention discloses a construction method and application of a gene modified mesenchymal stem cell. The construction method comprises the following steps: constructing a recombinant lentivirus carrying PD-L1 and ICAM1 genes; the recombinant lentivirus carrying the PD-L1 gene and the ICAM1 gene is transfected with mesenchymal stem cells, and the mesenchymal stem cells are screened by puromycin, so that an engineered mesenchymal stem cell strain modified by the PD-L1 gene and the ICAM1 gene is obtained; the mesenchymal stem cells provided by the invention are modified by engineering genes of PD-L1 and ICAM1, and are screened by puromycin to obtain a mesenchymal stem cell strain capable of stably and highly expressing the genes of PD-L1 and ICAM1; after the mesenchymal stem cells highly expressing the PD-L1 and ICAM1 genes are intravenously injected into an autoimmune hepatitis animal model, the autoimmune hepatitis symptom can be remarkably relieved, the liver injury degree can be reduced, the expression of inflammatory factors can be regulated, the inflammatory reaction can be inhibited, and the obvious curative effect can be achieved.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

The invention belongs to the technical field of biological medicine, and particularly relates to a chondroitin sulfate oligosaccharide derivative and a preparation method and application thereof.The structure of the chondroitin sulfate oligosaccharide derivative is shown in the formula I # imgabs0 #, in the formula I, R1 is SO3H and R2 is H or R1 is H and R2 is SO3H, and the polymerization degree of the chondroitin sulfate oligosaccharide derivative is equal to 8; the chondroitin sulfate oligosaccharide derivative has good chronic hepatitis repair promotion and anti-inflammatory activity, is clear in structure, and can be orally taken to treat the non-alcoholic fatty liver disease.

The invention relates to gardenia polysaccharide as well as a preparation method and application thereof. The gardenia polysaccharide comprises the following monosaccharide units: rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, or mainly comprises rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose; the molar ratio of rhamnose to glucuronic acid to galacturonic acid to glucose to galactose to arabinose in the gardenia polysaccharide is (3-15): (1-8): (4-18): (1-6): (15-35): (25-70). According to the gardenia polysaccharide, FFA induced mouse primary parenchymal hepatic cell lipid accumulation can be reduced, no obvious cytotoxic effect exists, CDAHFD diet induced hepatic fibrosis can be reduced, and the gardenia polysaccharide has a good effect of preventing and / or treating non-alcoholic steatohepatitis.

The present application belongs to the field of biomedicine technology, and specifically relates to a chondroitin sulfate oligosaccharide derivative and a preparation method and application thereof. The structure of the chondroitin sulfate oligosaccharide derivative is shown in Formula I, #imgabs0#Formula I, where R1 is SO3H, R2 is H or R1 is H, R2 is SO3H, and the polymerization degree of the chondroitin sulfate oligosaccharide derivative is equal to 8; the chondroitin sulfate oligosaccharide derivative has good promotion of chronic hepatitis repair and anti-inflammatory activity, and has a clear structure, and can be used for oral treatment of non-alcoholic fatty liver disease.

The invention relates to an Akecman mucophilic protein strain LWHK0003, which has the effects of preventing non-alcoholic steatohepatitis, resisting obesity, preventing NASH induced by GAN diet, maintaining constant blood sugar and resisting inflammation.

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

The invention provides an application of intestinal tract Ticam1 in regulation and control of MASH intestinal tract inflammatory response, the application is characterized in that the Ticam1 in the intestinal tract is inhibited, the growth of Ackermania mucilaginosa is promoted, and the strain code QAA37749.1 is used for catalyzing the conversion of betaine and improving MASH. The invention also provides an application of the intestinal tract Ticam1 in preparation of an MASH drug and a corresponding MASH treatment drug. Research finds that Ticam1 can aggravate intestinal injury of HFD mice, and deletion of Ticam1 in IEC can relieve HFD-induced hepatitis and hepatic fibrosis, improve HFD-induced metabolic disorder and cause change of intestinal microbiome, and further experiment and analysis are combined to obtain an influence mechanism of Ticam1 on MASH, so that a new thought and approach are provided for preparation of MASH treatment drugs, and the application has a broad application prospect. And the method has a remarkable application prospect.

The invention discloses a respiration guiding device used in a liver cancer three-dimensional conformal radiotherapy process, and relates to the technical field of respiration guiding, the respiration guiding device comprises an abdominal respiration detection device and an alarm device, the abdominal respiration detection device is composed of a mounting base cloth and a plurality of film pressure sensors, and the film pressure sensors are all mounted in the mounting base cloth; four elastic lacing belts are symmetrically installed on the abdominal respiration detection device, two pieces of installation connecting cloth are installed on the four elastic lacing belts, and the respiration guiding device is composed of the abdominal respiration detection device, the elastic lacing belts, the installation connecting cloth, a first fixing assembly, a second fixing assembly, alarm equipment and a soft elastic sleeve. According to the three-dimensional radiotherapy device, the patient can be prompted to reduce abdominal activity and carry out thoracic respiration, so that the three-dimensional radiotherapy is promoted to irradiate a target focus more effectively, the damage of radiotherapy to surrounding normal tissues is reduced, and the incidence rate of radiation hepatitis, radiation pneumonitis and radiation cholecystitis is reduced.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

To provide a composition for improving liver health.SOLUTION: In one aspect, the composition of the present invention includes a complex component of Gallocatechin Gallate and Isoquercitrin, which effectively reduces oxidative stress and chronic inflammatory reaction that occur during the accumulation of lipids in liver tissue, thereby improving liver health and enabling the prevention, improvement, or treatment of various liver diseases such as hepatitis, cirrhosis, and liver cancer.SELECTED DRAWING: Figure 1

The invention discloses a liver-targeted exosome polydopamine silicon nano drug delivery system as well as a preparation method and application thereof, and relates to the field of inflammatory microenvironment targeted controlled-release drug delivery. The system is composed of exosome, active oxygen response bond modified mesoporous silica, PDA and an anti-inflammatory drug, the water solubility of natural medicinal compounds such as TB can be remarkably improved, the bioavailability can be improved, the effects of in-vivo and in-vitro specific targeted inflammation sites and efficient liver protection and hepatitis treatment can be achieved, the biotoxicity of TB is remarkably reduced, and the application prospect is broad. The compound is expected to be applied to safe and efficient acute liver injury treatment and prevention of natural medicinal compounds such as TB, so that a nanotechnology delivery strategy is provided for clinical application of other natural product monomers; the invention has important fundamental research significance and pre-clinical application value in the fields of accurate treatment, prevention and health care of acute hepatitis and acute liver injury.

The invention discloses a method for exploring the influence of hepatic hydatid on hepatitis, and belongs to the technical field of medical research. The method comprises the following steps: selecting liver echinococcosis cases and viral hepatitis cases from hospitals in areas with high incidence of echinococcosis; collecting detailed medical history data of the screened case patients; counting the collected data, establishing a database, comparing various index differences of hepatic hydatid combined hepatitis cases and pure viral hepatitis cases, and preliminarily analyzing the influence of hepatic hydatid on hepatitis; selecting a research object and pairing patients in a control group; establishing a follow-up visit queue, and regularly carrying out follow-up visit on the research object and the control group patients; and counting follow-up data of the research object and the control group of patients, and analyzing the influence of the hepatic hydatid on the hepatitis. According to the method for exploring the influence of the hepatic hydatid on the hepatitis, the influence of the hepatic hydatid on the hepatitis is comprehensively and deeply explored, and a powerful basis is provided for clinical diagnosis, treatment and prevention.

The invention relates to the technical field of animal model construction, and discloses a non-alcoholic steatohepatitis model and a construction method and application thereof. The construction method comprises the following steps: performing stable overexpression on an AKT gene in the liver of a mouse by adopting a high-pressure caudal vein transfection technology, and feeding the mouse by adopting a high-fat feed. The non-alcoholic steatohepatitis model constructed by the construction method provided by the invention has the characteristics of liver inflammatory cell infiltration, liver fat deposition, insulin resistance, dyslipidemia and the like, has high clinical pathology similarity with NASH, has a remarkable steatohepatitis phenotype, can be used for researching the occurrence and development mechanism of NASH and evaluating the treatment effect of drugs, and has a wide application prospect. The method is of great significance to prevention and treatment of generation and development of NASH; meanwhile, the construction method is simple to operate, does not need transgenic animals, is short in feeding period, low in cost and high in efficiency, can effectively shorten the establishment period of the non-alcoholic steatohepatitis animal model, and has a good application prospect.

The present invention relates to the medical use of specific long-acting glycemic analogs having dual GLP-1 / glycemic receptor agonist activity for the prevention and / or treatment of metabolic liver diseases, in particular non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-related hepatic fibrosis and / or cirrhosis.

The present invention discloses the application of the combined drug of mecobalamin (MeCbl) and Shuilinjia (SC) in the treatment of non-alcoholic steatohepatitis (NASH). The present invention firstly proposes that oral MeCbl can effectively intervene in and treat the progression of NASH disease, and firstly proposes that the combined drug of oral MeCbl and SC can synergistically enhance the treatment of NASH, as well as liver injury, inflammation, liver fibrosis and hepatic lipid deposition on the basis of monomeric drugs. The MeCbl / SC composition in the present invention has a potent effect on the treatment of NASH, provides a new therapeutic drug for such refractory liver diseases clinically, while reducing the single-drug use dose of SC, and reducing the incidence of adverse reactions and treatment costs of patients. The pharmacokinetics and safety data of the drug molecules involved in the present invention are relatively detailed, and the development of new indications can quickly enter clinical evaluation, saving development costs while shortening the R & D cycle.

The present invention discloses an application of FN-1501 and its pharmaceutical composition in the preparation of drugs for preventing and / or treating liver injury, specifically including drugs for preventing and treating autoimmune hepatitis, viral hepatitis or drug-induced liver injury, especially drugs for preventing and treating autoimmune hepatitis. It can achieve multiple pharmacological effects of improving liver tissue structure damage, liver inflammation, reducing serum transaminase, serum lactate dehydrogenase and mRNA levels of inflammatory factors, and can play a therapeutic role at the gene level, molecular level and tissue level. There are no toxic side effects in the body, and the preparation form used is wide. The appropriate drug dosage form can be selected according to the clinical application scenario, which provides a new development strategy for targeted drugs for the prevention and treatment of liver injury.

The invention discloses a substituted heterocyclic compound containing an α-ketone skeleton and a use thereof, and relates to the field of pharmaceutical chemistry, and specifically relates to a substituted heterocyclic compound containing an α-ketone skeleton or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing these compounds and their medical uses, in particular, an application of the substituted heterocyclic compound as a fatty amide hydrolase (FAAH) inhibitor in the preparation of a drug for preventing or treating diseases related to FAAH, including inflammatory diseases, rheumatoid arthritis, hepatitis, liver fibrosis, autoimmune diseases, pain, depression, pain-depression comorbidity, autism, social phobia, Tourette syndrome, neurodegenerative diseases, anxiety post-traumatic stress (PTSD), cannabinoid use disorder, drug withdrawal, and anti-tumor treatment.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of LAP3 and an agonist thereof in macrophage immune inflammation mediated diseases. The invention provides application of leucine aminopeptidase 3 or leucine aminopeptidase 3 agonist substances in preparation of drugs for prevention, treatment and / or adjuvant treatment of macrophage immune inflammation mediated diseases. According to the invention, it is found for the first time that the expression level of LAP3 in macrophages is increased under an acute stress condition, and the limiting effect of LAP3 on generation and development of sepsis and acute hepatitis is disclosed; the invention discloses that the knockout of the LAP3 can remodel a macrophage metabolic network, reduce oxidative phosphorylation, promote ROS (reactive oxygen species) production and activate TAK1, thereby promoting the activation of a downstream inflammation signal channel and finally promoting macrophage inflammation. A new target spot and a theoretical basis can be provided for clinical diagnosis and treatment of macrophage-mediated inflammation by illuminating the effect of LAP3 on regulating and controlling macrophage inflammation and a molecular mechanism of LAP3.

In the present specification, disclosed is a method for preparing a gallocatechin gallate (Gallocatable Gallate), which comprises the steps of: preparing a gallocatechin gallate (Gallocatable Gallate; the present invention relates to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, in particular to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, such as GCG, isoquercitrin, IQC, and to the preparation of a composition for enhancing liver health or for auxiliary protection against chemical liver injury. In one aspect, the composition of the present invention can include a composite component of gallocatechin gallate and isoquercitrin to effectively reduce oxidative stress and chronic inflammatory response occurring in the process of lipid accumulation in liver tissue to improve liver health, and is applied to prevention, improvement or treatment of various liver diseases such as hepatitis, cirrhosis, liver cancer and the like.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

The present invention pertains to a method or a pharmaceutical composition of new ovatodiolide derivative compounds, AR100-RA1-Cys and AR100-RA1-ST, which have shown unexpected effects in treating autoimmune diseases, characterized by hepatocellular inflammation, such as autoimmune hepatitis, diabetes mellitus type 1, Sjogren's syndrome, multiple sclerosis and psoriasis. Also provided are the synthetic processes for compound preparation.

The present invention relates to food and pharmaceutical compositions for relieving endoplasmic reticulum stress to suppress or prevent various diseases caused by endoplasmic reticulum stress. More specifically, the present invention relates to a food and pharmaceutical composition for preventing or treating fatty liver symptoms or hepatitis, comprising a lysate of any one selected from the group consisting of Saccharomyces cerevisiae KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14983BP, KCTC 14984BP, and KCTC 14985BP, or a mixture thereof.

The invention discloses an application of a benzofuro [3, 2-c] quinolinone compound in prevention and treatment of metabolic dysfunction related steatohepatitis. For example, a compound P82, namely 3, 8-dihydroxybenzofuro [3, 2-c] quinoline-6 (5H)-ketone, which is prepared through synthesis and purification of an intermediate, can obviously improve liver fatty degeneration, inflammatory infiltration and fibrosis in an HFHC-induced metabolic dysfunction-related steatohepatitis model, so that the progress of metabolic dysfunction-related steatohepatitis is effectively delayed; meanwhile, liver cell lipid accumulation induced by oleic acid and palmitic acid can be improved, so that the compound is expected to be developed into a new medicine for preventing and treating metabolic dysfunction related steatohepatitis.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The invention provides application of a stevia rebaudiana extract, and belongs to the technical field of pure natural plant extracts, the stevia rebaudiana extract at least contains phenols, flavones and potassium ions, and when a health care product and / or a composition are given to a subject, at least one of the following components is achieved: antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity and the like. The expression of IRS protein, tyrosine phosphorylation of IRS and the content of GLUT4 protein are increased; bacteria are inhibited, and viruses and allergy are resisted; the intraocular pressure is reduced; the appetite is promoted; the hair loss is prevented or the hair growth is promoted. The application comprises application of the stevia rebaudiana extract in preparation of hair loss preventing or hair growth promoting products. The health-care product containing the stevia rebaudiana extract can prevent or treat type 2 diabetes mellitus, inhibit bacteria or resist viruses or allergy, and can be used as auxiliary food and / or sports food for sub-health people, type 2 diabetes mellitus patients, patients receiving glaucoma treatment, cancer patients, hepatitis patients, overweight people, picky and anorexia children or patients during general disease rehabilitation. The hair loss can be prevented or the hair growth is promoted.